Indicator Explorer

Indicator description
Indicator: SP/Fansidar use during pregnancy
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took at least one dose of SP/Fansidar
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_SPF
Indicator description
Indicator: SP/Fansidar 2+ doses during pregnancy
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took two or more doses of SP/Fansidar
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_2SP
Indicator description
Indicator: SP/Fansidar 3+ doses during pregnancy
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took three or more doses of SP/Fansidar
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_3SP
Indicator description
Indicator: SP/Fansidar use during antenatal visit
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took at least one dose of SP/Fansidar, with at least one dose during an antenatal care visit
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_SPA
Indicator description
Indicator: SP/Fansidar 2+ doses, at least one during ANC visit
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took two or more doses of SP/Fansidar, with at least one dose during an antenatal care visit
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_2SA
Indicator description
Indicator: SP/Fansidar 3+ doses, at least one during ANC visit
Measure: Percent
Definition: Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took three or more doses of SP/Fansidar, with at least one dose during an antenatal care visit
Denominator: Women with a live birth in the two years preceding the survey
Group: Use of IPTp by women during pregnancy
Universe: Women
Type: Indicator
Decimals: 1
Indicator ID: ML_IPTP_W_3SA
DHS Quickstats Indicators

  Indicator Name Indicator Definition Indicator Denominator  
SP/Fansidar use during pregnancy Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took at least one dose of SP/Fansidar Women with a live birth in the two years preceding the survey (W)
SP/Fansidar 2+ doses during pregnancy Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took two or more doses of SP/Fansidar Women with a live birth in the two years preceding the survey (W)
SP/Fansidar 3+ doses during pregnancy Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took three or more doses of SP/Fansidar Women with a live birth in the two years preceding the survey (W)
SP/Fansidar use during antenatal visit Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took at least one dose of SP/Fansidar, with at least one dose during an antenatal care visit Women with a live birth in the two years preceding the survey (W)
SP/Fansidar 2+ doses, at least one during ANC visit Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took two or more doses of SP/Fansidar, with at least one dose during an antenatal care visit Women with a live birth in the two years preceding the survey (W)
SP/Fansidar 3+ doses, at least one during ANC visit Percentage of women age 15-49 with a live birth in the two years preceding the survey who during the pregnancy took three or more doses of SP/Fansidar, with at least one dose during an antenatal care visit Women with a live birth in the two years preceding the survey (W)